European Journal of Biomedical and Pharmaceutical Sciences

DIAGNOSIS OF TUBERCULOSIS IN PLHIV PATIENTS BY USING THE XPERT® MTB/RIF ASSAY: A CLINICAL STUDY

Dr. Atul Kharate, Dr. Vijay Agrwal, Dr. Vijay Chhajlani, Dr. Jyoti Khurana*, Neha Dawar, Amit Verma, Dhwani Patel and Nagmi Aliya Ansari

ABSTRACT

Objective: Tuberculosis (TB) is one of the commonest opportunistic infection and the leading cause of death in HIV patients in developing countries. HIV infection is a well recognised risk factor for both activation of initial infection and reactivation of latent infection. This study was done to find out the co-prevalence and the trend of HIV infection among tuberculosis patients and to determine the prevalence of MDR Tuberculosis in HIV positive patients using Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, United States). Materials and Methods: The sputum samples are received from Indore M.P, India. Sputum samples of the patients with symptoms suggestive of pulmonary tuberculosis including both new cases and on treatment are received from the various DMCs and hospitals. Sputum specimen was processed for TB detection by Cartridge Based Nucleic Acid Amplification testing (CB-NAAT) using Xpert MTB/RiF assay technology. Results: The study period is from 2015 to August 2016. A total of 4595 patients with symptoms suggestive of pulmonary tuberculosis including both new cases and on treatment. Out of these patients 1087 were reported MTB detected. Out of these 4595 patients 953 were reported HIV positive and out of 953 patients 127(13.3%) were reported positive for (HIV +TUBERCULOSIS). Of these 127 cases 118(92.9%) cases were sensitive to rifampicin (RIF) and 9(7%) cases were showing resistance to rifampicin (RIF) Drug. Conclusion: Co-existence of HIV and tuberculosis is high and there is high Prevalence of MDR tuberculosis in HIV patients.

Keywords: Co-infection, Cartridge based nucleic acid amplification testing, Human immunodeficiency virus (HIV), Pulmonary, Rifampicin, Tuberculosis.